China shows way in new pharma race: Own meds, don’t just make ’em

Conventional assessments of pharmaceutical geopolitics revolve around manufacturing clusters. China’s extensive drug supply chain, India’s dominance in cost-effective generics, and the concentration of patent‑protected research in wealthier nations have long shaped this perspective. Nevertheless, this paradigm is evolving. Two notable advances within China over the past week signal a deeper commitment to endogenous drug production. Jiangsu Province stands at the forefront of this transformation, positioning the region as a cornerstone of China’s emerging strategy to secure its own therapeutic portfolio rather than relying solely on foreign imports.

A feature highlighting this breakthrough appeared shortly after its release by Asia Times.

Source link